β-actin-luc - Model 11977

Random Transgenic

Mixed Background

  • Model #
  • Genotype
  • Nomenclature
  • 11977-F
    tg/wt
    B6.Cg-Tyrtm1Arte Tg(Actb-luc)46Xen
  • 11977-M
    tg/wt
    B6.Cg-Tyrtm1Arte Tg(Actb-luc)46Xen
  • Carries a 14 kb fragment of the murine β-actin promoter isolated from genomic DNA, a chimeric intron and modified firefly luciferase cDNA (Promega pGL3). This model was produced by backcrossing of model 10500 to B6 albino to produce the beta-actin luciferase mouse in a fully congenic B6 background.
  • Basal expression of the reporter is expected to be similar to that of model 10500: highest in skeletal muscle, thymus, skin, heart, bone, pancreas, and is detectable in all tissues, including white blood cells
  • The reporter is constitutively expressed and is not significantly inducible
  • Useful as a donor animal for studying the transplantation of various tissue types
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Origin:

The β-actin-luc mouse (model 10500) was developed by Caliper Life Sciences. The model was created by microinjecting a transgene containing a fragment of the murine β-actin promoter isolated from genomic DNA, a chimeric intron and modified firefly luciferase cDNA from pGL3. This transgene was microinjected into FVB/N zygotes. The resultant mice from founder line 46 were bred to FVB/NTac mice. The line was backcrossed the equivalent of 4-5 times onto the C57BL/6J-Tyrc-2J and intracrossed to make the coat color mutation homozygous. Taconic received stock from Caliper in 2010, and the line was embryo transfer derived. In the production colony, line 10500 was maintained by mating mice which are wild type to those which are hemizygous for the luciferase transgene. Model 10500 was then backcrossed to B6 Albino to produce the beta-actin luciferase mouse in a fully congenic B6 background.


Color:

Albino

Species:

Mouse

Initial Publication:

There is no specific publication describing the generation of these mice, but multiple publications exist demonstrating applications using the model 10500.

 

Other publications:

Cheeran MC, Mutnal MB, Hu S, Armien A, Lokensgard JR. (2009) Reduced lymphocyte infiltration during cytomegalovirus brain infection of interleukin-10-deficient mice. J Neurovirol. 15(4):334-42.

Murphy CT, Moloney G, Macsharry J, Haynes A, Faivre E, Quinlan A, McLean PG, Lee K, O'Mahony L, Shanahan F, Melgar S, Nally K. (2010) Technical Advance: Function and efficacy of an {alpha}4-integrin antagonist using bioluminescence imaging to detect leukocyte trafficking in murine experimental colitis. J Leukoc Biol. 88(6):1271-8.

Murphy CT, Moloney G, Hall LJ, Quinlan A, Faivre E, Casey P, Shanahan F, Melgar S, Nally K. (2010) Use of bioluminescence imaging to track neutrophil migration and its inhibition in experimental colitis. Clin Exp Immunol. 162(1):188-96.

Schachtele SJ, Hu S, Little MR, Lokensgard JR. (2010) Herpes simplex virus induces neural oxidative damage via microglial cell Toll-like receptor-2. J Neuroinflammation. 7:35.

 



Conditions of Use
Title to the LPTA® Models is not transferred to researcher. Researcher has only the following limited rights to use the LPTA® Models. Researcher may obtain derivatives from the LPTA® Models, consisting of tissues or organs, for their research use, however researcher shall have no right to establish luciferase containing cell lines from such derivatives. Researcher may not breed or propagate the LPTA® Models without the prior express written consent of Taconic. Researcher may not transfer the LPTA® Models or any derivatives to a third party. TACONIC MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED,INCLUDING FOR NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE LPTA® MODELS.

Use of the LPTA® Models may require a license to perform certain methods of non-invasive in vivo imaging of mammals that are covered by patents controlled by Caliper Life Sciences, Inc., including without limitation U.S. Patent Nos. 5,650,135; 6,217,847; 7,198,774; 6,649,143; 6,939,533; 6,916,462; 6,923,951; 6,890,515; and 6,908,605. The purchase of the LPTA® Models does not convey any license rights under such patents. Researcher should contact Caliper Life Sciences, Inc. to obtain license rights to such patents.